New clinical evidence reveals that even light-to-moderate alcohol consumption significantly accelerates progression from fatty liver disease to cirrhosis and liver cancer in people with diabetes and obesity. The newly recognized MetALD classification acknowledges alcohol as a cofactor that works synergistically with metabolic dysfunction, resulting in higher all-cause, cancer-related, and liver-related mortality compared to metabolic dysfunction-associated steatotic liver disease alone. This finding challenges conventional wisdom about "safe" drinking levels for metabolically compromised individuals. The research landscape has largely focused on heavy drinking's liver effects, but this work highlights how alcohol acts as both a direct liver toxin and an indirect contributor to insulin resistance and dyslipidemia in already vulnerable populations. For the 80+ million Americans with diabetes or severe obesity who have fatty liver disease, this represents a paradigm shift requiring alcohol screening integration into routine metabolic care. The practical implications are immediate: clinicians must now assess alcohol use using tools like the AUDIT questionnaire and phosphatidylethanol testing, while patients with metabolic conditions should reconsider any alcohol consumption as a modifiable risk factor for liver disease progression.